News

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023…

7 months ago

Epic Bio to Present at Upcoming BMO Biopharma Spotlight Series Event

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene…

7 months ago

HCA Healthcare Taps Nudj Health to Provide Remote Patient Monitoring Services to Patients

PASADENA, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Nudj Health, a tech-enabled health service that delivers evidence-based mental health and…

7 months ago

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned companyLEXINGTON, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE)…

7 months ago

Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group

FORT LEE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and…

7 months ago

Revolutionary Partnership in Behavioral Health: Nabla Copilot and Opus EHR Join Forces to Enhance Clinical Practice with Powerful AI

MIAMI, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Nabla and Opus EHR, two trailblazing names in the healthcare technology sector, have…

7 months ago

Conduent’s BenefitWallet HSA Portfolio Moving to HealthEquity

FLORHAM PARK, N.J. and DRAPER, Utah, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Conduent Incorporated (Nasdaq: CNDT), a global technology-led business…

7 months ago

Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development

Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need Parexel Gwyn Bebb, BM, BCh., Ph.D., Senior Vice…

7 months ago

Elutia Announces Private Placement for Proceeds Up to $26 Million

– Combined proceeds of financing and Orthobiologics divestiture potentially top $60 million – SILVER SPRING, Md., Sept. 19, 2023 (GLOBE…

7 months ago

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development

YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the…

7 months ago